

ADVISORY COMMISSION ON DRUG ABUSE AND CONTROLLED SUBSTANCES (HACDACs)

Alcohol and Drug Abuse Division (ADAD), Department of Health (DOH), State of Hawai'i

Kākuhihewa Building, 601 Kamokila Boulevard, Room 360, Kapolei, Hawai'i

January 24, 2023

9:00 am – 11:00 am

Members Present: Ku'ulei Salzer-Vitale, MSW, MPA Chair; Greg Tjapkes, Vice Chair; Kathi Calles (Fujii); Diana Felton, MD; Jon Fujii, MBA; Lilinoe Kauahikaua, MSW; John Paul Moses, III, APRN-R

Members Absent: Adam Gratz, DO; Erika Vargas, LCSW

Staff Present: John Valera, AICP; Robyn Loudermilk, AICP

Guests Present: Dr. Daryl Shorter, Opioid Response Network; Kimberly Kua-Medeiros, Opioid Response Network; and Ruth Baker, Department of Accounting and General Services, Procurement Policy Board

AGENDA ITEM	DISCUSSION	RECOMMENDATIONS/ ACTIONS/ CONCLUSIONS	PERSON(S) RESPONSIBLE	DUE DATE
1. Call to Order:	The meeting was called to order at 9:00.			
2. Consideration and approval of meeting minutes of October 25, 2022, and November 28, 2022.	Motion by Commissioner Felton and seconded by Commissioner Calles to adopt minutes from the October 24, 2022, meeting. Motion approved. Motion by Commissioner Felton and seconded by Commissioner Calles to adopt minutes from the November 28, 2022, meeting. Motion approved.	Motions approved.		
3. Community Input: [Pursuant to section 92-3, Hawaii Revised Statutes, all interested persons will have three (3) minutes to speak, i.e., per person, per item, or written testimony can be submitted on agenda items]	No community members present to offer input.			
4. Update from the Alcohol and Drug Abuse Division (ADAD) on the State Plan Revision Project.	<u>State Plan Revision Project</u> <ul style="list-style-type: none"> Comments received provided technical amendments to the Comprehensive Chapter. 			

AGENDA ITEM	DISCUSSION	RECOMMENDATIONS/ ACTIONS/ CONCLUSIONS	PERSON(S) RESPONSIBLE	DUE DATE
	<ul style="list-style-type: none"> • In light of the Governor’s State of the State Address (SOS) and his correspondence with Chief Justice Recktenwald, there will be an emphasis on the intersection of mental health and the criminal justice system. • Comments continue to be accepted on both the Comprehensive Chapter and the Behavior Health Dashboard-beta. <p><u>Legislative Session 2023</u></p> <ul style="list-style-type: none"> • The Session has begun. There are bills related to alcohol tax, prohibiting methadone clinics within 750 feet of a school, decriminalizing fentanyl test strips for testing purposes, opioid bills, and a feasibility study of prescription digital therapeutics. • In response to a question on the methadone clinic bill, Mr. Valera relayed that Senator Rhodes introduced SB983, however at this time does not know who introduced its companion bill HB378. This measure is being introduce on behalf of a constituent. • In response to a question on what in the Governor’s SOS would lead to the revision of the current State Plan, Mr. Valera relayed that ADAD would double check the current plan with the Governor’s SOS. There is potential for ADAD to establish additional partnerships, particularly for the housing part. This could include recovery capacity i.e., clean and sober homes and other types of facilities that may be pilot projects. • There are not many recovery support facilities statewide. ADADs Clean and Sober Home registry has 64 houses listed; informally there are about 200 statewide. ADAD needs to develop an outreach program to encourage current operators 			

AGENDA ITEM	DISCUSSION	RECOMMENDATIONS/ ACTIONS/ CONCLUSIONS	PERSON(S) RESPONSIBLE	DUE DATE
	<p>to be listed on the registry. There is also a need to expand recovery options.</p> <ul style="list-style-type: none"> • Commissioner Moses shared that his patients have told him that they are in sober and/or semi-sober homes that do not enforce abstinence and are known as drug houses. As a provider it would be useful to know which houses do and do not enforce abstinence. • ADAD is only aware of homes on its registry and does not think that any homes on the registry are damp/wet. Commissioner Moses to look at ADADs Clean and Sober registry and confer with patients. <p><u>Staffing</u></p> <ul style="list-style-type: none"> • There are two interviews this week for Program Specialists. In the meantime, there are a number of 89-day hires. Over half of ADADs openings are external recruitments through the Department of Human Resources Development (DHRD). ADAD is waiting for DHRD to post the positions. 			
<p>5. Planning meeting topics and presentations for upcoming Hawaii Advisory Committee on Drug Abuse and Controlled Substances (HACDACS) meetings:</p> <p>Update on meeting topics and presentations for:</p> <ul style="list-style-type: none"> • January 2023 • February 2023 • March 2023 • April 2023 • May 2023 • <p>Brainstorming ideas for topics and speakers in:</p>	<p>Chair Salzer led the group in discussion related to planning, and any schedules or topics that the group would like to discuss:</p> <p>The following is the tentative monthly schedule:</p> <ul style="list-style-type: none"> • February 2023 – Cannabis Taskforce Update. • March 2023 – Substance use in Native Hawaiian community and cultural healing. • April 2023 – The University of Hawaii Mapuna Lab • May 2023 – Law Enforcement Perspective on Fentanyl • June 2023 – Trauma Informed Recovery Oriented System of Care 	<p>Contact Cannabis Taskforce to present update on activities.</p> <p>Contact Papa Ola Lokai to present on their current project on substance use in Native Hawaiian community and cultural healing.</p>	<p>Mr. Valera to contact taskforce.</p> <p>Commissioner Kauahikaua confirmed Papa Ola Lokahi.</p>	

AGENDA ITEM	DISCUSSION	RECOMMENDATIONS/ ACTIONS/ CONCLUSIONS	PERSON(S) RESPONSIBLE	DUE DATE
<ul style="list-style-type: none"> • June 2023 • July 2028 <p>Potential topics include medical cannabis safety and testing policies; harm reduction review based on substance use; status of residential treatment programs and their trends and needs, prevention initiatives, medication assisted treatment for methamphetamine use disorder, the intersection of substance use treatment and the criminal justice system. New topic ideas are encouraged.</p>	<ul style="list-style-type: none"> • July 2023 – Recovery Communities (National and/or Local) • August 2023 – Recovery Communities (National and/or Local) • September 2023 – Legislative Report • October 2023 – Legislative Report • November 2023 – Legislative Report <p>Discussion then focused on existing HACDACS opening(s) and current members who terms will expire on June 30, 2023. The current opening is for a member from the corrections community. Terms expire on June 30, 2023, for Commissioners Moses, J. Fujii, and Kauahikaua.</p>	<p>Contact Mapuna Lab.</p> <p>Contact Gary Yabuta, Executive Director of Hawaii High Intensity Drug Trafficking Area (HIDTA)</p> <p>Contact Tia Roberts Hartsock, Director Office of Wellness and Resilience.</p> <p>Contact Faces and Voice of Recovery.</p> <p>Contact Aunty Shari from Hale Pomaikai</p>	<p>Commissioner Kauahikaua confirmed Mapuna Lab.</p> <p>Commissioner Calles to follow up with Gary Yabuta.</p> <p>Mr. Valera to contact Office of Wellness and Resilience.</p> <p>Commissioner Kauahikaua to contact both Faces & Voices of Recovery and Aunty Shari from Hale Pomaikai.</p>	
<p>6. Hawaii Opioid Initiative Report:</p> <p>Updates and progress from the Hawaii Opioid Initiative workgroups where HACDACS members are currently serving.</p>	<p>Workgroup 1-Treatment Access</p> <ul style="list-style-type: none"> • Upcoming meeting on 1/27/2023. <p>Workgroup 2 – Prescriber Education</p> <ul style="list-style-type: none"> • The group has not met in a long time. <p>Workgroup 4 – Prevention & Public Education</p> <ul style="list-style-type: none"> • Discussed the distribution of the resource cards and discussed the development of Workgroup 8 and adjusting the objectives. <p>Workgroup 6 – Law Enforcement & First Responders</p> <ul style="list-style-type: none"> • No meeting in December. No future meeting date at this time. 			

AGENDA ITEM	DISCUSSION	RECOMMENDATIONS/ ACTIONS/ CONCLUSIONS	PERSON(S) RESPONSIBLE	DUE DATE
	<ul style="list-style-type: none"> Mr. Valera informed the Commission that the resource cards have come in and are ready to be distributed. Additionally, SAMHSA recently made changes to the DATA waiver; it is no longer required. 			
7. Presentation on Medication Assisted Treatment.	<p>Dr. Daryl Shorter, from the Opioid Response Network, presentation on evidence-based medication treatments for Stimulant Use Disorder (StUD) covered the following areas:</p> <ul style="list-style-type: none"> Best practices in behavior therapies for treating Stimulant use Disorder; Summarize the evidence base for promising medications for Stimulant Use Disorder; and List medication options under investigation for treatment of comorbid Opioid and Stimulant Use Disorder. <ul style="list-style-type: none"> Need to ask the question: what symptoms are you trying to treat? Behavioral therapies for StUD that are evidence supported include: contingency management, cognitive behavioral therapy/relapse prevention, community reinforcement approach, and motivational interviewing. Other strategies which may be useful include; physical exercise, matrix model, family or couples therapy, and mindfulness meditation. There are currently no FDA-approved medications for treatment of StUD, however, several medications hold promise. Promising medications for Methamphetamine Use Disorder include; bupropion, mirtazapine, naltrexone, and methylphenidate. Promising medications for Cocaine Use Disorder include; bupropion, topiramate, mixed AMPH salts & topiramate, and Modafinil. Medication options under investigation include naltrexone with buprenorphine and buprenorphine with naloxone (suboxone) Also need to ask the question: what is the patient's goal? Discussion focused on topiramate dosing, anecdotes on what is working, and high-level policy barriers. There are factors that need to be taken into consideration with increasing topiramate doses. Also, with a high dosage (300 mg), there are concerns with cognitive dulling and use for weight loss. Anecdotally seeing benefits from establishing relationships for treatment retention and a patient's willingness to engage in evidence-based psychotherapy. High-level policy barriers that hold back work include geographic location of addiction services and medication determines who get access, contingency management works- increase dollar amount limit (offer incentives), and the combination of contingency management and medication. 			

AGENDA ITEM	DISCUSSION	RECOMMENDATIONS/ ACTIONS/ CONCLUSIONS	PERSON(S) RESPONSIBLE	DUE DATE
8. Open Forum: Public comment on issues not on the agenda, for consideration of Board's agenda at the next meeting.	No community members present for open forum discussion.			
9. Adjournment	The meeting was adjourned at 10:41 am			

Next Meeting: February 28, 2023
9:00 am to 11:00 am
Zoom Meeting